...OncoGenex and Sonus completed their previously announced merger to form OncoGenex Pharmaceuticals Inc. The combined company... ...expected to last until 1Q09 (see BioCentury, June 2). OncoGenex Technologies Inc. , Vancouver, B.C. Sonus Pharmaceuticals Inc....
...received an exclusive, worldwide license to preclinical caspase activators from Bayer’s Bayer Healthcare LLC unit. Sonus... ...compounds for cancer. Bayer retains rights to develop the non-core compounds for all other indications. Sonus... ...front and is eligible for undisclosed milestones, plus royalties. Further financial terms were not disclosed. Sonus Pharmaceuticals Inc....
...OncoGenex and Sonus completed their previously announced merger to form OncoGenex Pharmaceuticals Inc. The combined company... ...expected to last until 1Q09 (see BioCentury, June 2). OncoGenex Technologies Inc. , Vancouver, B.C. Sonus Pharmaceuticals Inc....
...received an exclusive, worldwide license to preclinical caspase activators from Bayer’s Bayer Healthcare LLC unit. Sonus... ...compounds for cancer. Bayer retains rights to develop the non-core compounds for all other indications. Sonus... ...front and is eligible for undisclosed milestones, plus royalties. Further financial terms were not disclosed. Sonus Pharmaceuticals Inc....